Skip to content

Visual Function Evaluation of Bilateral AcrySof ReSTOR Aspheric IOL

Visual Function After Implantation of Bilateral AcrySof ReSTOR Aspheric Intraocular Lens (IOL): Postmarket Evaluation

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00818116
Enrollment
34
Registered
2009-01-07
Start date
2008-12-31
Completion date
Unknown
Last updated
2010-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cataracts

Keywords

Cataract, visual acuity, AcrySof ReSTOR Aspheric Intraoculare Lens, Bilateral cataract

Brief summary

The objective of this study is to evaluate postoperative visual function in patients implanted bilaterally with the ReSTOR Aspheric Intraocular Lens (IOL).

Interventions

DEVICEAcrySof ReSTOR Aspheric IOL

Bilateral implantation with the AcrySof ReSTOR Aspheric Intraocular Lens (IOL) for the replacement of cataract in the natural lens of the eye.

Sponsors

Alcon Research
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
50 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Bilateral cataract patients who require natural crystalline lens removal and bilateral Intraocular Lens (IOL) implantation. * 50\ 75 years of age * \<1 Diopter of astigmatism preoperatively (before surgery) as measured by Keratometry readings.

Exclusion criteria

* Patients with pre-existing conditions that could skew the results. * Any of conditions before and during surgery specified in the product information.

Design outcomes

Primary

MeasureTime frameDescription
Uncorrected and Best Corrected Visual Acuities (Near and Distance)6 Months Following Cataract SurgeryMeasurement of uncorrected (without spectacles or other visual corrective devices) and best-corrected (with spectacles or other visual corrective devices)visual acuity at both near and distance. Visual Acuity (VA) is measured in logMAR. LogMAR is the logarithm of the minimum angle of resolution. A lower logMAR value indicates better visual acuity.

Countries

United States

Participant flow

Recruitment details

34 eligible patients were enrolled into the study

Pre-assignment details

Open-label, single arm, non-randomized

Participants by arm

ArmCount
ReSTOR Aspheric
Implantation with the AcrySof ReSTOR Aspheric Intraocular Lens (IOL)
34
Total34

Baseline characteristics

CharacteristicReSTOR Aspheric
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
20 Participants
Age, Categorical
Between 18 and 65 years
14 Participants
Sex: Female, Male
Female
24 Participants
Sex: Female, Male
Male
10 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
1 / 34
serious
Total, serious adverse events
0 / 34

Outcome results

Primary

Uncorrected and Best Corrected Visual Acuities (Near and Distance)

Measurement of uncorrected (without spectacles or other visual corrective devices) and best-corrected (with spectacles or other visual corrective devices)visual acuity at both near and distance. Visual Acuity (VA) is measured in logMAR. LogMAR is the logarithm of the minimum angle of resolution. A lower logMAR value indicates better visual acuity.

Time frame: 6 Months Following Cataract Surgery

ArmMeasureGroupValue (MEAN)Dispersion
ReSTOR AsphericUncorrected and Best Corrected Visual Acuities (Near and Distance)Near Uncorrected Visual Acuity0.02 logMARStandard Deviation 0.08
ReSTOR AsphericUncorrected and Best Corrected Visual Acuities (Near and Distance)Near Best-Corrected Visual Acuity0.01 logMARStandard Deviation 0.07
ReSTOR AsphericUncorrected and Best Corrected Visual Acuities (Near and Distance)Distance Uncorrected Visual Acuity0.00 logMARStandard Deviation 0.07
ReSTOR AsphericUncorrected and Best Corrected Visual Acuities (Near and Distance)Distance Best-Corrected Visual Acuity-0.03 logMARStandard Deviation 0.07

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026